We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.65%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$342M
AUM Growth
-$111M
Cap. Flow
-$71.8M
Cap. Flow %
-21.01%
Top 10 Hldgs %
35.85%
Holding
99
New
15
Increased
34
Reduced
31
Closed
19

Top Buys

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$8.15M
2
IRTC icon
iRhythm Holdings
IRTC
+$5.39M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$5.36M
4
LEGN icon
Legend Biotech
LEGN
+$4.76M
5
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$4.36M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$13M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.9M
3
AVTR icon
Avantor
AVTR
+$8.89M
4
DXCM icon
DexCom
DXCM
+$8.82M
5
DHR icon
Danaher
DHR
+$6.18M

Sector Composition

Rank Sector Weight
1 Healthcare 96.94%
2 Industrials 2.69%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EIGR
76
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$415K 0.12%
+1,667
New +$263K
RCKT icon
77
Rocket Pharmaceuticals
RCKT
$374M
$401K 0.12%
+25,295
New +$437K
MTEM
78
DELISTED
Molecular Templates, Inc.
MTEM
$358K 0.1%
6,914
-2,935
-30% -$130K
NRIX icon
79
Nurix Therapeutics
NRIX
$2.76B
$289K 0.08%
20,663
-67,161
-76% -$1.19M
VSTM icon
80
Verastem
VSTM
$629M
$269K 0.08%
15,896
+618
+4% +$10.6K
ANGO icon
81
AngioDynamics
ANGO
$651M
– –
-87,969
Closed -$2.43M
AZTA icon
82
Azenta
AZTA
$1.47B
– –
-36,554
Closed -$3.77M
ETNB
83
DELISTED
89bio
ETNB
– –
-152,098
Closed -$1.99M
HALO icon
84
Halozyme
HALO
$11.6B
– –
-41,333
Closed -$1.66M
HCA icon
85
HCA Healthcare
HCA
$89.8B
– –
-50,661
Closed -$13M
ICAD
86
DELISTED
iCAD Inc
ICAD
– –
-103,302
Closed -$744K
IONS icon
87
Ionis Pharmaceuticals
IONS
$9.39B
– –
-80,238
Closed -$2.44M
KOD icon
88
Kodiak Sciences
KOD
$2.72B
– –
-35,174
Closed -$2.98M
QTRX icon
89
Quanterix
QTRX
$139M
– –
-20,000
Closed -$848K
RGEN icon
90
Repligen
RGEN
$9.35B
– –
-10,331
Closed -$2.74M
RPID icon
91
Rapid Micro Biosystems
RPID
$84.8M
– –
-100,000
Closed -$1.06M
SMLR
92
DELISTED
Semler Scientific
SMLR
– –
-21,419
Closed -$1.96M
STXS icon
93
Stereotaxis
STXS
$139M
– –
-413,218
Closed -$2.56M
VERA icon
94
Vera Therapeutics
VERA
$2.16B
– –
-21,555
Closed -$576K
XBI icon
95
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.5B
– –
-100,000
Closed -$11.2M
XRAY icon
96
Dentsply Sirona
XRAY
$2.27B
– –
-73,566
Closed -$4.1M
ONCT
97
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
– –
-14,464
Closed -$657K
CSLT
98
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-625,678
Closed -$964K
HZNP
99
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-100,747
Closed -$10.9M
1 2 3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Parkman Healthcare Partners held 99 positions worth $342M, down 25% from $453M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Parkman Healthcare Partners withdrew a net $71.8M in Q1 2022, closing 19 positions and reducing 31 holdings. Its most notable exit was HCA Healthcare, an estimated $13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

Against the trend, Parkman Healthcare Partners opened a new position in Neurocrine Biosciences worth $5.93M.

  • Parkman Healthcare Partners's largest Q1 2022 buy was Neurocrine Biosciences: 63,234 shares worth $5.93M.
  • Parkman Healthcare Partners added most to Tenet Healthcare in Q1 2022, an estimated $8.15M increase.
  • Parkman Healthcare Partners's biggest Q1 2022 reduction was Avantor, cutting an estimated $8.89M.
  • Parkman Healthcare Partners fully exited HCA Healthcare in Q1 2022, selling an estimated $13M.
  • Parkman Healthcare Partners's ten largest holdings make up 36% of its $342M portfolio in Q1 2022.
  • Parkman Healthcare Partners opened 15 new positions and closed 19 in Q1 2022.
  • Parkman Healthcare Partners's portfolio value fell 25% quarter-over-quarter to $342M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.